Merck & Co. is no longer in talks to acquire biotech firm Revolution Medicines Inc. after the two companies couldn’t agree on ...
Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best S&P 500 Dividend Stocks to Buy in 2026. On January 20, TD Cowen ...
The drugmaker had recently been in discussions to acquire RevMed in a deal that could have valued the cancer-drug biotech at ...
The pharmaceutical giant had been in talks to buy the cancer drug developer in a transaction that could have valued ...
Investors are apparently taking bets on when Revolution will be acquired. A handful of pharmas could be interested as Merck ...
Revolution Medicines shares tumbled in premarket trading Monday after The Wall Street Journal reported that drugmaker Merck is no longer in talks to buy the cancer-drug biotech. Shares of Revolution, ...
Revolution Medicines shares drop after Merck buyout talks collapse over price. Deal was valued at $28-32B before negotiations ...
By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...
Corcept’s overall survival data “look competitive” with AbbVie’s Elahere and Merck’s blockbuster Keytruda, Truist Securities ...
The company’s previous CCO was Cristal Downing, who joined Insulet as chief corporate affairs officer late last year.
The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...
Jan 21 (Reuters) - Merck & Co unit MSD and the Coalition for Epidemic Preparedness Innovations said on Wednesday they have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results